论文部分内容阅读
目前抗纤溶剂虽在原发性蛛网膜下腔出血(SAH) 患者的应用已基本成为临床常规,但就其对脑血管痉挛(CVS)发生率的影响各家学者观点不一。本报道就我单位85～87年收治的SAH住院病人58例临床观察结合文献资料及抗纤溶剂对复发性出血率的影响讨论分析。一般资料本组男36例,女22例,年龄为18～81岁,<40岁12例,40～50岁21例,50岁以上者25例。动态发病44例,静态发病14例。发病开始即有意识障碍者25例,2例伴抽搐,
At present, although antifibrinolytic agents have become a routine clinical application in patients with primary subarachnoid hemorrhage (SAH), scholars have different opinions on the incidence of cerebral vasospasm (CVS). This report on my unit 85 to 87 years of SAH hospitalized patients with clinical observation of 58 cases of literature and anti-fibrinolytic agents on the impact of recurrent bleeding were analyzed. General information The group of 36 males and 22 females, aged 18 to 81 years, <40 years in 12 cases, 40 to 50 years in 21 cases, 25 years of age over 25 years. 44 cases of dynamic disease, static disease in 14 cases. 25 patients with impaired consciousness at onset, 2 with convulsions,